Metabolomic profiling of blood and urine in teens with asthma
Official title: Metabolomics in the Diagnosis and Treatment of Asthma in Children
Run by I.M. Sechenov First Moscow State Medical University · NCT07280364 · Data updated 2026-11-12
This project will test whether specific blood and urine metabolites can identify asthma flare-ups in teenagers aged 12–17.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 12 Years to 17 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | I.M. Sechenov First Moscow State Medical University Academic / other |
| Locations | 1 site (Moscow) |
| Status | Recruiting |
| Started | March 13, 2024 |
| Main results expected | June 2026 |
| Study ends | August 2026 |
| Registry record updated | January 28, 2026 |
| Trial ID | NCT07280364 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adolescents 12–17 years old with a confirmed diagnosis of asthma who can give informed consent and be hospitalized at the study center, without severe concomitant somatic, metabolic, or endocrine diseases.
✕Probably not a fit
Children younger than 12, those without a confirmed asthma diagnosis, patients with serious comorbid conditions, or those unable/unwilling to be hospitalized are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will enroll about 100 children aged 12–17 with a confirmed diagnosis of bronchial asthma and group them by disease severity and by whether they are having an exacerbation. A separate subgroup receiving targeted therapy will also be included, and all participants will be hospitalized in the pulmonology department for sample collection. Blood and urine samples will be taken at admission for all patients and again around day 10 for those experiencing an exacerbation, alongside spirometry measurements and the Asthma Control Test. Participants will receive their usual physician-prescribed asthma treatments throughout the study while samples are analyzed by metabolomic methods to look for metabolite patterns linked to exacerbations.
Why it matters
Potential benefit: If successful, this could help clinicians detect or predict asthma exacerbations and guide more personalized treatment for adolescents.
How similar studies have gone: Prior metabolomics studies in asthma have shown promising metabolite signals related to severity and exacerbations but results remain exploratory and not yet widely validated for clinical use.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age from 12 to 17 years old * Confirmed diagnosis of asthma * Informed voluntary consent to participate in the study Exclusion Criteria: * age under 12 years * no established diagnosis of asthma * concomitant severe somatic, metabolic, and endocrine diseases * patient's withdrawal of informed consent
Where it's running
-
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Moscow, Russia Recruiting
Study contacts
- Principal investigator: Natalia A. Geppe, MD, Doctor of M.Sc., Professor — I.M. Sechenov First Moscow State Medical University
- Study coordinator: Natalia A. Geppe, MD, Doctor of M.Sc, Professor
- Email: geppe@mail.ru
- Phone: +7-499-248-44-22
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Chronic Respiratory Disease Participant Engagement
This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.
-
HB0056 in adults with moderate to severe asthma
This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.
-
Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations
This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.
-
Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma
This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.
-
Biologics for Type 2 Inflammation in Asthma and COPD in Real World
This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.
-
GSK5784283 vs placebo in uncontrolled asthma (PERSIST ASTHMA-2)
A new medicine called GSK5784283 is being tested to see if it lowers asthma flare-ups better than a placebo in people with uncontrolled asthma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.